Ascendis Pharma A/S (ASND)
230.53
+4.93
(+2.19%)
USD |
NASDAQ |
Sep 28, 14:33
Ascendis Pharma Research and Development Expense (TTM) : 315.81M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 315.81M |
| March 31, 2026 | 309.75M |
| December 31, 2025 | 332.30M |
| September 30, 2025 | 326.63M |
| June 30, 2025 | 329.46M |
| March 31, 2025 | 338.49M |
| December 31, 2024 | 323.90M |
| September 30, 2024 | 339.21M |
| June 30, 2024 | 381.60M |
| March 31, 2024 | 407.55M |
| December 31, 2023 | 447.12M |
| September 30, 2023 | 460.18M |
| June 30, 2023 | 437.04M |
| March 31, 2023 | 418.93M |
| December 31, 2022 | 398.40M |
| September 30, 2022 | 362.65M |
| June 30, 2022 | 333.82M |
| March 31, 2022 | 338.07M |
| December 31, 2021 | 350.91M |
| September 30, 2021 | 366.18M |
| June 30, 2021 | 371.79M |
| Date | Value |
|---|---|
| March 31, 2021 | 341.37M |
| December 31, 2020 | 298.56M |
| September 30, 2020 | 261.73M |
| June 30, 2020 | 237.07M |
| March 31, 2020 | 215.29M |
| December 31, 2019 | 209.22M |
| September 30, 2019 | 199.09M |
| June 30, 2019 | 185.53M |
| March 31, 2019 | 185.22M |
| December 31, 2018 | 165.46M |
| September 30, 2018 | 155.11M |
| June 30, 2018 | 152.60M |
| March 31, 2018 | 128.78M |
| December 31, 2017 | 113.21M |
| September 30, 2017 | 101.75M |
| June 30, 2017 | 86.03M |
| March 31, 2017 | 76.93M |
| December 31, 2016 | 72.87M |
| September 30, 2016 | 65.03M |
| June 30, 2016 | 55.53M |
| March 31, 2016 | 54.52M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| BioMarin Pharmaceutical, Inc. | 766.68M |
| Novo Nordisk A/S | 8.086B |
| Evaxion AS | 10.27M |
| Genmab A/S | 1.781B |
| Zealand Pharma A/S | 286.45M |